University of Michigan medtech spin-off Tangent Medical Technologies is now accepting commercial orders of the firm’s NovaCath IV catheter following four years of development.

The Ann Arbor-based spin-off said it will begin deliveries of its catheter in the third quarter of the year, beginning next month.

To date, Tangent has attracted $13.1m in venture funding to develop its catheter, which won US Food and Drug Administration approval last year. It received $4.5m in 2011 led by venture firms Arboretum Ventures…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?